Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2023-04-17 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于深圳信立泰药业股份有限公司分拆所属子公司深圳信立泰医疗器械股份有限公司至科创板上市事宜股票交易自查期间相关内幕信息知情人买卖股票情况的自查报告之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed self-inspection report by China International Capital Corporation Limited (中国国际金融股份有限公司) regarding insider trading activities during the period of a spin-off and listing of a subsidiary company (深圳信立泰医疗器械股份有限公司) on the STAR Market (科创板). It includes detailed disclosures of stock transactions by insiders, employees, controlling shareholders, and related parties, along with their statements and commitments about compliance with insider trading laws. The document references regulatory rules related to spin-offs, insider information management, and securities laws. It is a specialized report focusing on insider trading compliance and related stock transactions during a corporate restructuring event. This type of document is not a general annual or interim financial report, nor is it a simple announcement or presentation. It is a compliance and audit-related report focusing on insider trading and stock transaction self-inspection during a significant corporate event. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and regulatory compliance investigations excluding full annual reports. Q1 2023
2023-04-17 Chinese
关于举行2022年年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding the 2022 annual performance briefing (业绩说明会) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references that the 2022 Annual Report and its summary have already been disclosed on March 29, 2023. The document invites investors to participate in an online performance explanation meeting scheduled for April 14, 2023, with company executives attending. The text does not contain the actual annual report or detailed financial data but rather announces the event where the report will be discussed. The document length is short (742 characters), and it serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits best under Investor Presentation (IP).
2023-04-07 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司2022年度内部控制评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control evaluation report verification opinion for the year 2022 by a sponsoring institution (华英证券有限责任公司) for Shenzhen Xinlitai Pharmaceutical Co., Ltd. It discusses the internal control evaluation, scope, standards, and conclusions about the effectiveness of internal controls related to financial reporting and non-financial reporting. The document is a verification or audit opinion on the internal control evaluation report rather than the full internal control report itself. It does not contain full financial statements or comprehensive financial data but rather an opinion on the internal control report. The document length is 3390 characters, which is relatively short and consistent with an opinion or verification letter. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2022
2023-03-28 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司使用自有闲置资金投资理财产品的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring securities company regarding Shenzhen Salubris Pharmaceuticals Co., Ltd.'s use of idle funds to invest in low-risk short-term financial products. It includes investment purpose, amount, methods, risk analysis, internal controls, and opinions from independent directors and the supervisory board. It is not a financial report like an annual or interim report, nor is it a regulatory announcement or certification. It is a formal audit or verification opinion related to the company's financial activities but not a full audit report or annual report. This fits best under Audit Report / Information (AR) as it is a standalone audit/verification opinion on a specific financial matter. FY 2024
2023-03-28 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. for cash management. It includes specifics about the raised funds, investment projects, cash management products, risk analysis, and approvals by the board, supervisory committee, independent directors, and the sponsor. The document references regulatory guidelines and confirms compliance and proper procedures. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a formal audit or verification opinion related to the use of funds and compliance with regulatory requirements, which fits the definition of an Audit Report / Information (AR). The document length (5381 characters) and content indicate it is the report itself, not just an announcement or certification letter, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2022
2023-03-28 Chinese
关于拟续聘2023年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm for the fiscal year 2023. It details the audit firm's qualifications, independence, fees, and the approval process by the board and audit committee. It does not contain any actual audit reports or financial statements but rather discusses the intention to appoint the auditor and the procedural steps involved. The document length is 4048 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters and the appointment of the audit firm, but it is not the audit report itself. However, given the short length and nature of the document as an announcement of auditor appointment, it aligns more closely with a Regulatory Filing (RNS) as it is a formal disclosure about audit arrangements rather than the audit report or results themselves. Hence, the most appropriate classification is Regulatory Filings (RNS).
2023-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.